14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VCYT vs FLGT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Fulgent Genetics, Inc. (FLGT) is the stronger overall head-to-head candidate over Veracyte, Inc. (VCYT) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas FLGT carries 33.3/100 (SELL) at $24.07 (7.7x Forward P/E, -37.1% operating margin).
Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. FLGT 33.3/100 SELL), FLGT captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-37.1% vs. 15.0% operating margin) and revenue trajectory (+7.5% vs. +15.1% YoY).
Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile FLGT trades in a Markup technical trend (BREAKOUT options phase, RSI 59.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Diagnostics & Research value chain with $689.0M market capitalization and -37.1% operating margin.
OpEx & R&D Reinvestment70.9% of Rev ($234M)
90D Engineering Disclosures0 Published
Investor FAQ VCYT vs FLGT Key Questions & Quantitative Answers
As of Nov 16, 2026, Fulgent Genetics, Inc. (FLGT) is the stronger overall head-to-head candidate over Veracyte, Inc. (VCYT) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas FLGT carries 33.3/100 (SELL) at $24.07 (7.7x Forward P/E, -37.1% operating margin). Composite vs. Pillar Nuance: While VCYT currently prints a higher short-term Unified Composite Score (49.1/100 HOLD vs. FLGT 33.3/100 SELL), FLGT captures the overall institutional head-to-head verdict (4–6 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-37.1% vs. 15.0% operating margin) and revenue trajectory (+7.5% vs. +15.1% YoY). Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile FLGT trades in a Markup technical trend (BREAKOUT options phase, RSI 59.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VCYT leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with FLGT at +7.5% YoY revenue growth and -98.6% YoY earnings growth on $330M TTM revenue (33.8% gross margin, -37.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while FLGT shifted +1500.0%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus 70.9% of Rev ($234M) (0 disclosures) for FLGT.
FLGT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas FLGT trades at 7.7x Forward P/E, 7.7x Trailing P/E, 1.32x PEG, and 1.9x EV/Revenue (-0.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus FLGT (-8.7% ROE) capital efficiency.
In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, FLGT carries 67.5% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.10β · 110% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.